MeiraGTx Shares Hit 52-Week High After Blindness-Treatment Data Release

Dow Jones

Feb 22, 2025

By Josh Beckerman

Shares of MeiraGTx Holdings shares reached a 52-week high after the company said 11 children treated to date in a drug study gained visual acuity after treatment.

The stock was recently up 9.1%, to $7.45, Friday after touching an intraday high of $7.80. Shares are up about 23% since the start of the year.

The genetic-medicines company reported results from a study of rAAV8.hRKp.AIPL1 in children who were legally blind at birth with AIPL1-associated severe retinal dystrophy.

A paper published in The Lancet presents data for the first four, who were treated unilaterally. Following the strong safety and substantial efficacy demonstrated in this cohort, another seven have now been treated bilaterally.

"With these truly exceptional results in hand, we are working with global regulators on expedited approval of rAAV8.hRKp.AIPL1 to provide access to babies born with AIPL1-related LCA4," the company said.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

February 21, 2025 14:41 ET (19:41 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2513111692"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2513111692\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2513111692?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-22 03:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2513111692","market":"nz","top_or_hot":-1,"title":"MeiraGTx Shares Hit 52-Week High After Blindness-Treatment Data Release","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of MeiraGTx Holdings shares reached a 52-week high after the company said 11 children treated to date in a drug study gained visual acuity after treatment. \n</p>\n<p>\n  The stock was recently up 9.1%, to $7.45, Friday after touching an intraday high of $7.80. Shares are up about 23% since the start of the year. \n</p>\n<p>\n  The genetic-medicines company reported results from a study of rAAV8.hRKp.AIPL1 in children who were legally blind at birth with AIPL1-associated severe retinal dystrophy. \n</p>\n<p>\n  A paper published in The Lancet presents data for the first four, who were treated unilaterally. Following the strong safety and substantial efficacy demonstrated in this cohort, another seven have now been treated bilaterally. \n</p>\n<p>\n  \"With these truly exceptional results in hand, we are working with global regulators on expedited approval of rAAV8.hRKp.AIPL1 to provide access to babies born with AIPL1-related LCA4,\" the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 21, 2025 14:41 ET (19:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MeiraGTx Shares Hit 52-Week High After Blindness-Treatment Data Release</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeiraGTx Shares Hit 52-Week High After Blindness-Treatment Data Release\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-22 03:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of MeiraGTx Holdings shares reached a 52-week high after the company said 11 children treated to date in a drug study gained visual acuity after treatment. \n</p>\n<p>\n  The stock was recently up 9.1%, to $7.45, Friday after touching an intraday high of $7.80. Shares are up about 23% since the start of the year. \n</p>\n<p>\n  The genetic-medicines company reported results from a study of rAAV8.hRKp.AIPL1 in children who were legally blind at birth with AIPL1-associated severe retinal dystrophy. \n</p>\n<p>\n  A paper published in The Lancet presents data for the first four, who were treated unilaterally. Following the strong safety and substantial efficacy demonstrated in this cohort, another seven have now been treated bilaterally. \n</p>\n<p>\n  \"With these truly exceptional results in hand, we are working with global regulators on expedited approval of rAAV8.hRKp.AIPL1 to provide access to babies born with AIPL1-related LCA4,\" the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 21, 2025 14:41 ET (19:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2513111692","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2513111692","pubTimestamp":1740166860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of MeiraGTx Holdings shares reached a 52-week high after the company said 11 children treated to date in a drug study gained visual acuity after treatment.The stock was recently up 9.1%, to $7.45, Friday after touching an intraday high of $7.80. Shares are up about 23% since the start of the year.The genetic-medicines company reported results from a study of rAAV8.hRKp.AIPL1 in children who were legally blind at birth with AIPL1-associated severe retinal dystrophy.A paper published in The Lancet presents data for the first four, who were treated unilaterally. Following the strong safety and substantial efficacy demonstrated in this cohort, another seven have now been treated bilaterally.\"With these truly exceptional results in hand, we are working with global regulators on expedited approval of rAAV8.hRKp.AIPL1 to provide access to babies born with AIPL1-related LCA4,\" the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MGTX":"Meiragtx Holdings Plc"},"translate_title":"失明治疗数据发布后MeiraGTx股价触及52周高点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MGTX":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Shares of MeiraGTx Holdings shares reached a 52-week high after the company said 11 children treated to date in a drug study gained visual acuity after treatment. \n\n\n  The stock was recently up 9.1%, to $7.45, Friday after touching an intraday high of $7.80. Shares are up about 23% since the start of the year. \n\n\n  The genetic-medicines company reported results from a study of rAAV8.hRKp.AIPL1 in children who were legally blind at birth with AIPL1-associated severe retinal dystrophy. \n\n\n  A paper published in The Lancet presents data for the first four, who were treated unilaterally. Following the strong safety and substantial efficacy demonstrated in this cohort, another seven have now been treated bilaterally. \n\n\n  \"With these truly exceptional results in hand, we are working with global regulators on expedited approval of rAAV8.hRKp.AIPL1 to provide access to babies born with AIPL1-related LCA4,\" the company said. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 21, 2025 14:41 ET (19:41 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}